Close Menu

NEW YORK (GenomeWeb) – Karius said today that Nohla Therapeutics will use Karius' next-generation sequencing plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101, in acute myeloid leukemia patients with chemotherapy-induced neutropenia.

Karius' test uses NGS to detect microbial cell-free DNA in plasma from more than a thousand pathogens from a single blood draw. The test will enable Nohla to easily monitor immunocompromised patients for infections, including from bacteria, DNA viruses, fungi, and protozoa.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.